Novo Nordisk A/S (NVO)vsOshkosh Corporation (OSK)
NVO
Novo Nordisk A/S
$36.33
-1.52%
HEALTHCARE · Cap: $165.02B
OSK
Oshkosh Corporation
$147.89
+0.85%
INDUSTRIALS · Cap: $9.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 2865% more annual revenue ($309.06B vs $10.42B). NVO leads profitability with a 33.1% profit margin vs 6.2%. NVO appears more attractively valued with a PEG of 4.88. NVO earns a higher WallStSmart Score of 55/100 (C).
NVO
Buy55
out of 100
Grade: C
OSK
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-59.4%
Fair Value
$24.21
Current Price
$36.33
$12.12 premium
Margin of Safety
-156.1%
Fair Value
$68.14
Current Price
$147.89
$79.75 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 61 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 44.5%
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Revenue declined 7.6%
Earnings declined 4.7%
3.5% revenue growth
6.2% margin — thin
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.
Bull Case : OSK
The strongest argument for OSK centers on P/E Ratio, Price/Book.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.
Bear Case : OSK
The primary concerns for OSK are Revenue Growth, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
NVO profiles as a declining stock while OSK is a value play — different risk/reward profiles.
OSK carries more volatility with a beta of 1.35 — expect wider price swings.
OSK is growing revenue faster at 3.5% — sustainability is the question.
OSK generates stronger free cash flow (526M), providing more financial flexibility.
Bottom Line
NVO scores higher overall (55/100 vs 48/100), backed by strong 33.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Oshkosh Corporation
INDUSTRIALS · FARM & HEAVY CONSTRUCTION MACHINERY · USA
Oshkosh Corporation designs, manufactures and markets specialty vehicles and bodies worldwide. The company is headquartered in Oshkosh, Wisconsin.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?